Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin reaction could give prescribers pause as the race to challenge Novo Nordisk's dominance intensifies. Lilly reported headline results from the first phase three trial of retatrutide in type 2 diabetes, showing patients achieved 16.8% weight loss and a 1.1 percentage point reduction in HbA1c, a standard measure of long-term blood sugar control, after 40 weeks at the 12mg dose. The gut tolerability numbers, closely watched given that nausea and vomiting have dogged the entire GLP-1 drug class, came in at levels broadly in line with Lilly's own approved Zepbound and Novo Nordisk's pipeline drug CagriSema. Nausea affected 26.5% of patients, diarrhoea 22.8% and vomiting 17.6%. The wrinkle is dysesth
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial [Yahoo! Finance]Yahoo! Finance
- LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]Yahoo! Finance
- RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results [Yahoo! Finance]Yahoo! Finance
- Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? [Yahoo! Finance]Yahoo! Finance
- Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- 3/17/26 - Form 4
- LLY's page on the SEC website